The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery
Status:
Completed
Trial end date:
2017-07-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if patients undergoing acetabular ORIF (open
reduction with internal fixation) who receive tranexamic acid have a reduced risk of
allogenic blood transfusion, perioperative blood loss, wound complication and higher risk for
thromboembolic events compared to patients who receive placebo. Investigators want to
determine the cost-effectiveness related to allogenic blood transfusion as a blood loss
management strategy in acetabular open reduction internal fixation (ORIF). Orthopaedic
surgery carries with it a significant risk for blood loss. Current management of
perioperative blood loss is the use of allogenic blood transfusion. Allogenic blood
transfusion carries with it a risk for HIV and Hepatitis C as well as multiple adverse
reactions. There have been significant efforts to reduce the use of allogenic blood
transfusion in orthopaedic surgery. Tranexamic acid, an anti-fibrinolytic agent, has been
used in management of blood during surgery. In order to determine the impact of tranexamic
acid in reducing blood loss among patients undergoing acetabular ORIF, investigators will
conduct a prospective randomized study. Patients undergoing acetabular surgery will be
screened for this study. Patients will be then randomized to placebo or tranexamic acid which
will be administered during and after surgery. The following data will be collected: patient
characteristics, surgery information, blood loss, blood transfusions, wound complication
within 30 days of surgery, and cost.